Scientist Luke Hoeppner, PhD, Receives $50K Award From The American Cancer Society
"Standard therapy for SCLC patients has not substantially improved since the introduction of chemotherapeutic agents over 30 years ago because oncogenic drivers remain poorly understood. Recent advances in immunotherapy have proven effective against some types of SCLC, but immunotherapy is not effective in many cases of SCLC. New strategies to treat small cell lung cancer are urgently needed.”